PDCD1 and neoplasm: Based on these findings, we hypothesized that tumor-resident T clones may dynamically exchange with peripheral blood, anti-PD-1 therapy reinvigorates neoantigen-specific CD8+ T clones in peripheral blood, and peripherally expanded CD8+ T cells migrated to tumor lesions to produce the anti-tumor response.